Volume 5, Issue 11: Benefits of CFTR Modification Beyond FEV1 Improvement
e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 5, Issue 11)
Target Audience
Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.
Learning Objectives
After participating in this activity, the participant will demonstrate the ability to:
- Summarize the newer advances in our understanding of the pathophysiology of cystic fibrosis and how CFTR modulation may influence this process
- Describe the effects of CFTR modulation on nutritional status.
- Evaluate the observational data supporting the impact of CFTR modulation on chronic infection in cystic fibrosis
Christopher Goss, MD
Professor
Division of Pulmonary and Critical Care Medicine
Professor of Pediatrics
University of Washington Medical Center
Seattle, Washington
Disclosure
Dr. Christopher Goss reports that he has research grant funding from Vertex Pharmaceuticals Inc. In addition he has received honoraria from Gilead Sciences and F. Hoffman-La Roche Ltd.
Unlabeled/Unapproved Uses
Dr. Christopher Goss has reports that the activity will not contain any discussion of off-label or unapproved drugs or products.
Available Credit
- 1.00 ANCC
- 0.50 Attendance